These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 27729614)

  • 1. Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.
    van den Broek E; Krijgsman O; Sie D; Tijssen M; Mongera S; van de Wiel MA; Belt EJ; den Uil SH; Bril H; Stockmann HB; Ylstra B; Carvalho B; Meijer GA; Fijneman RJ
    Oncotarget; 2016 Nov; 7(45):73876-73887. PubMed ID: 27729614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer.
    van den Broek E; Dijkstra MJ; Krijgsman O; Sie D; Haan JC; Traets JJ; van de Wiel MA; Nagtegaal ID; Punt CJ; Carvalho B; Ylstra B; Abeln S; Meijer GA; Fijneman RJ
    PLoS One; 2015; 10(9):e0138141. PubMed ID: 26375816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer.
    Jorissen RN; Christie M; Mouradov D; Sakthianandeswaren A; Li S; Love C; Xu ZZ; Molloy PL; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Burgess AW; Busam D; Zhao Q; Strausberg RL; Lipton L; Desai J; Gibbs P; Sieber OM
    Br J Cancer; 2015 Sep; 113(6):979-88. PubMed ID: 26305864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
    Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
    Cell Oncol (Dordr); 2011 Jun; 34(3):215-23. PubMed ID: 21717218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of mutation profiling in patients with stage II and III colon cancer.
    Shen Y; Han X; Wang J; Wang S; Yang H; Lu SH; Shi Y
    Sci Rep; 2016 Apr; 6():24310. PubMed ID: 27074743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focus on 16p13.3 Locus in Colon Cancer.
    Mampaey E; Fieuw A; Van Laethem T; Ferdinande L; Claes K; Ceelen W; Van Nieuwenhove Y; Pattyn P; De Man M; De Ruyck K; Van Roy N; Geboes K; Laurent S
    PLoS One; 2015; 10(7):e0131421. PubMed ID: 26222184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
    Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
    Anal Cell Pathol (Amst); 2010; 33(2):95-104. PubMed ID: 20966546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
    Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer.
    Mayrhofer M; Kultima HG; Birgisson H; Sundström M; Mathot L; Edlund K; Viklund B; Sjöblom T; Botling J; Micke P; Påhlman L; Glimelius B; Isaksson A
    BMC Cancer; 2014 Nov; 14():872. PubMed ID: 25420937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected frequency of genomic alterations in histologically normal colonic tissue from colon cancer patients.
    Conconi D; Redaelli S; Bovo G; Leone BE; Filippi E; Ambrosiani L; Cerrito MG; Grassilli E; Giovannoni R; Dalprà L; Lavitrano M
    Tumour Biol; 2016 Oct; 37(10):13831-13842. PubMed ID: 27481518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
    Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
    Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative approach for prioritizing cancer genes in sporadic colon cancer.
    Reid JF; Gariboldi M; Sokolova V; Capobianco P; Lampis A; Perrone F; Signoroni S; Costa A; Leo E; Pilotti S; Pierotti MA
    Genes Chromosomes Cancer; 2009 Nov; 48(11):953-62. PubMed ID: 19672874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copy number variations in DCC/18q and ERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer.
    Sefrioui D; Vermeulin T; Blanchard F; Chapusot C; Beaussire L; Armengol-Debeir L; Sesboué R; Gangloff A; Hebbar M; Copin MC; Houivet E; Schwarz L; Clatot F; Tuech JJ; Bénichou J; Martin L; Bouvier AM; Sabourin JC; Sarafan-Vasseur N; Frébourg T; Lepage C; Michel P; Di Fiore F
    Int J Cancer; 2017 Apr; 140(7):1653-1661. PubMed ID: 28006840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer.
    Palacio-Rúa KA; Isaza-Jiménez LF; Ahumada-Rodríguez E; Muñetón-Peña CM
    Rev Gastroenterol Mex; 2014; 79(2):79-89. PubMed ID: 24861525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
    Gavin PG; Colangelo LH; Fumagalli D; Tanaka N; Remillard MY; Yothers G; Kim C; Taniyama Y; Kim SI; Choi HJ; Blackmon NL; Lipchik C; Petrelli NJ; O'Connell MJ; Wolmark N; Paik S; Pogue-Geile KL
    Clin Cancer Res; 2012 Dec; 18(23):6531-41. PubMed ID: 23045248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copy-number intratumor heterogeneity increases the risk of relapse in chemotherapy-naive stage II colon cancer.
    Lahoz S; Archilla I; Asensio E; Hernández-Illán E; Ferrer Q; López-Prades S; Nadeu F; Del Rey J; Sanz-Pamplona R; Lozano JJ; Castells A; Cuatrecasas M; Camps J
    J Pathol; 2022 May; 257(1):68-81. PubMed ID: 35066875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.